An analysis of the evolution of the written description requirement vis-à-vis DNA and biotechnological inventions.
The Federal Circuit uses particular patent doctrines as policy levers to control the nature of the nation's patent output. Most recently, the court has looked to the narrow implementation of the written description doctrine to limit the scope of biotechnology patents in general and DNA patents in particular. Recent case-law now indicates a slow evolution within the Federal Circuit to loosen this control and broaden the scope of DNA patents. This paper explores this evolution through a cursory review of the enigmatic written description requirement, examining particularly its history and purposes. It then examines some of the recent cases that allude to this Federal Circuit's policy shift. The paper then attempts to explain this evolution through the application of Public Choice Theory to the Court's decisions.
Greenbaum
Dov
D
Society in Science, Branco Weiss Fellowship, affiliated with the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. dov.greenbaum@aya.yale.edu
D001709:Biotechnology / Q000331:legislation & jurisprudence*; D004247:DNA; D010330:Patents as Topic / Q000331:legislation & jurisprudence*
D004247:DNA